Development Health & Wellbeing Life Sciences People

The Breakthroughs Are Here. Can Patients Live Long Enough to Reach Them? 

A pill that nearly doubles survival in pancreatic cancer and a one-off therapy that is giving paralysed-by-stiffness patients their lives back are rewriting medicine. For many patients, the hardest part now is the wait.

For decades, pancreatic cancer has been medicine’s most stubborn dead end. It is rarely caught early, it spreads quickly, and treatment options have barely moved in a generation. Fewer than one in seven patients survives five years. In Australia, almost two-thirds of those diagnosed die within twelve months.

Then, within a single year, two very different breakthroughs arrived. One is a daily tablet that attacks the protein driving most pancreatic cancers. The other is a re-engineered immune therapy, borrowed from cancer care, that is restoring movement in a rare and devastating neurological disease. Together they point to a genuine shift in what medicine can do. They also expose an uncomfortable question: how long should the sickest patients have to wait?

The “undruggable” target finally gives way

The story begins with RAS, a family of proteins that act as growth switches inside cells. When RAS mutates, the switch jams on and tumours grow unchecked. Mutations in this pathway drive more than 90 per cent of pancreatic cancers, yet for decades the protein was considered “undruggable”: its smooth structure gave drug molecules almost nothing to grip.

A drug called daraxonrasib, sold as Rasonque, found a workaround. Rather than clamping onto RAS directly, it acts as a “molecular glue”, bridging RAS to a second protein, cyclophilin A, and in doing so blocks RAS from sending its cancer-promoting signals. Because it does not depend on one specific mutation, it is the first pan-RAS inhibitor approved for any cancer.

The evidence behind it is striking. In the phase 3 RASolute 302 trial, 500 patients whose metastatic pancreatic cancer had already progressed on earlier treatment were assigned to either daraxonrasib or standard chemotherapy. Median overall survival was 13.2 months on the new drug against roughly 6.6 months on chemotherapy, a hazard ratio of 0.40, meaning a 60 per cent lower risk of death. Median time without disease progression rose from 3.5 months to 7.3 months in the main analysis group. The results were published in the New England Journal of Medicine.

The drug also appears easier to tolerate. Side effects forced 1.2 per cent of patients on daraxonrasib to stop treatment, compared with 11.2 per cent on chemotherapy.

Regulators moved with unusual speed. The US Food and Drug Administration approved Rasonque on 26 August 2026, about six and a half months ahead of its review deadline, for adults with metastatic pancreatic cancer who have had at least one prior systemic therapy or cannot take multi-drug chemotherapy. Trials are now testing it as a first-line treatment and after surgery.

A note of caution

It is not a cure. Oncologists writing in the Journal of Clinical Oncology have pointed out that trials stopped early can overstate benefits; at the time of analysis, median follow-up was only 8.5 months and many patients were still being tracked. Cancer experts also stress that the drug adds months, not decades. Even so, one commentary called it arguably the most important therapeutic advance this disease has seen, and a result that is unprecedented in a field where gains have long been measured in weeks.

An immune reset for a rare neurological disease

The second breakthrough comes from a different field entirely. Stiff person syndrome (SPS) is a rare autoimmune disorder of the central nervous system. It causes progressive muscle rigidity and painful spasms that can make walking, working and even sudden noises dangerous. Mayo Clinic first described it in 1956, and it came to wider attention when singer Céline Dion revealed her diagnosis in December 2022.

Existing treatments manage symptoms. A multicentre trial published in JAMA Neurology tested something more ambitious: CD19 CAR-T cell therapy, a technique pioneered in blood cancers. Doctors extract a patient’s own T cells, re-engineer them in a laboratory, and return them as a single treatment designed to reset the misfiring immune system.

The early results were dramatic. Jonathan Walden had reached the point where walking and basic daily tasks required his family’s help. After treatment he returned to full-time work, hunting and fishing, and says he has had no episodes since. Shari St. Germain, diagnosed in 2021, had stopped responding to standard therapies by 2024 and suffered falls triggered by sudden noise. Months after her infusion she was walking on a treadmill again.

Mayo neurologist Dr Anastasia Zekeridou said existing therapies can ease symptoms but very rarely restore patients to their previous level of function. The caveats are important: this was an early, non-randomised study at three sites, and the key unanswered question is whether the improvements last. Larger trials are the next step. If they succeed, the implication

s reach well beyond SPS, because many immune-mediated neurological conditions have few effective options.

The waiting room

The sharpest tension in this story is not scientific. It is about time.

In Australia, new medicines take a median of 22 months to be listed on the Pharmaceutical Benefits Scheme (PBS), the system that makes drugs affordable. Dee Ozolins, a 50-year-old Sydney mother of two, knows what that means. Diagnosed with terminal pancreatic cancer, she was given nine to 12 months to live. After surgery, chemotherapy and a spread to her lungs, early genomic testing led doctors to a clinical trial she qualified for. At one point she weighed just 35 kilograms. Today her cancer is stable and she has gained another year.

Her case shows what access to experimental treatment can mean, though it is not evidence that any particular drug works. What she cannot accept is the delay. “We die waiting,” she says.

The patient group Pankind Pancreatic Cancer Australia is campaigning under the banner Every Week Matters. It wants the federal government to adopt a recommendation from its 2024 Health Technology Assessment Review for a faster route to subsidy for promising treatments that meet urgent needs. Pankind says it has been working with the health minister’s office and that the government has signalled interest to the drug’s manufacturer, but the drug has yet to be submitted in Australia. Pancreatic cancer, advocates note, faces an extra disadvantage: patients often do not live long enough to build the long-running advocacy movements seen in other cancers.

The US has faced its own version of the problem. Even before approval, the FDA allowed expanded access to daraxonrasib for patients with few options, but reporting at the time described weeks-long waits and bureaucratic hurdles for some patients.

What happens next

The science is moving faster than the systems built to deliver it. Over the next year, watch for three things: whether first-line and post-surgery trials of daraxonrasib extend its benefit; whether the stiff person syndrome results hold up in larger trials; and whether health systems such as Australia’s find a way to shorten the gap between approval abroad and a prescription at home.

For patients, those answers cannot come soon enough. As science finally catches up with the disease, the measure of success may come down to something simple: how many people live long enough to benefit.

Leave a Reply

Your email address will not be published. Required fields are marked *